The expression and clinical significance of MyD88 in laryngeal cancer.
- Author:
Baocai LU
;
Wenyu DI
;
Rong LIAN
;
Zhenmin LU
;
Wenfa YU
- Publication Type:Journal Article
- MeSH:
Humans;
Laryngeal Neoplasms;
metabolism;
pathology;
Lymphatic Metastasis;
Myeloid Differentiation Factor 88;
metabolism;
Prognosis;
Survival Rate
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2015;29(16):1477-1479
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the myeloid differentiation factor 88 (MyD88) expression in laryngeal carcinoma and its clinical significance.
METHOD:Fifty-one patients with laryngeal carcinoma were collected, and all patients were confirmed by pathological diagnosis results. The expression of MyD88 protein was detected by immunohistochemical method in laryngeal cancer and its adjacent tissues to investigate the correlation among MyD88 expression, clinicopathological characteristics and prognosis of patients.
RESULT:The positive expression rate of MyD88 in laryngeal cancer tissues was 68.6%, significantly higher than that in normal tissues adjacent to carcinoma of which positive expression rate was 11.8%; MyD88 positive rate had nothing to do with laryngeal cancer patients age, sex, differentiation and tumour location (all P > 0.05), but correlated with clinical stage (P < 0.01) and lymph node metastasis (P < 0.05). In addition, the study also found that the expression of MyD88 quantity was inversely proportional with the five-year survival rate. The survival rate of patients with higher expression of MyD88 was significantly lower than that of patients with lower expression (P < 0.05).
CONCLUSION:MyD88 may be an important participant in the pathogenesis of laryngeal carcinoma, MyD88 targeted therapy may improve the prognosis of patients with laryngeal cancer.
